SWOG clinical trial number
CTSU/NRG-GY020

Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer

Open
Phase
Abbreviated Title
Testing the addition of the immunotherapy drug, pembrolizumab, to the usual radiation treatment for newly diagnosed early stage high intermediate risk endometrial cancer
Activated
02/07/2020
Participants
CTSU

Research committees

Early Therapeutics & Rare Cancers
Gynecologic Cancer

Treatment

MK-3475

Eligibility Criteria Expand/Collapse

Please review protocol eligibility criteria on the CTSU website (http://www.ctsu.org/) for more information.